Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + PD-1 in Locally Advanced or Metastatic Urothelial Carcinoma
NCT06405425Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in urothelial carcinoma (UC), sponsored by Biokin Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Started May 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06405425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405425.